Orbimed Advisors Llc - Net Worth and Insider Trading
Orbimed Advisors Llc Net Worth
The estimated net worth of Orbimed Advisors Llc is at least $3.7 Billion dollars as of 2024-06-05. Orbimed Advisors Llc is the Director, 10% Owner of Synthorx Inc and owns about 5,316,355 shares of Synthorx Inc (THOR) stock worth over $361 Million. Orbimed Advisors Llc is the Director, 10% Owner of Prevail Therapeutics Inc and owns about 13,822,463 shares of Prevail Therapeutics Inc (PRVL) stock worth over $318 Million. Orbimed Advisors Llc is also the Director, 10% Owner of Edgewise Therapeutics Inc and owns about 14,756,096 shares of Edgewise Therapeutics Inc (EWTX) stock worth over $257 Million. Besides these, Orbimed Advisors Llc also holds Loxo Oncology Inc (LOXO) , SpringWorks Therapeutics Inc (SWTX) , Audentes Therapeutics Inc (BOLD) , Principia Biopharma Inc (PRNB) , Enliven Therapeutics Inc (ELVN) , Turning Point Therapeutics Inc (TPTX) , Relypsa Inc (RLYP) , Rhythm Pharmaceuticals Inc (RYTM) , Supernus Pharmaceuticals Inc (SUPN) , ARS Pharmaceuticals Inc (SPRY) , NxStage Medical Inc (NXTM) , Third Harmonic Bio Inc (THRD) , Pacira BioSciences Inc (PCRX) , Theseus Pharmaceuticals Inc (THRX) , Mirati Therapeutics Inc (MRTX) , CTI BioPharma Corp (CTIC) , Fusion Pharmaceuticals Inc (FUSN) , Intellia Therapeutics Inc (NTLA) , Keros Therapeutics Inc (KROS) , Silverback Therapeutics Inc (SBTX) , Verona Pharma PLC (VRNA) , Terns Pharmaceuticals Inc (TERN) , Prelude Therapeutics Inc (PRLD) , Dimension Therapeutics Inc (DMTX) , ArriVent BioPharma Inc (AVBP) , Imara Inc (IMRA) , Compass Therapeutics Inc (CMPX) , CalciMedica Inc (CALC) , scPharmaceuticals Inc (SCPH) , NeuroPace Inc (NPCE) , Intercept Pharmaceuticals Inc (ICPT) , ORIC Pharmaceuticals Inc (ORIC) , Alpine Immune Sciences Inc (ALPN) , TELA Bio Inc (TELA) , Adicet Bio Inc (ACET) , 89bio Inc (ETNB) , Corvus Pharmaceuticals Inc (CRVS) , Constellation Pharmaceuticals Inc (CNST) , SI-BONE Inc (SIBN) , Janux Therapeutics Inc (JANX) , PMV Pharmaceuticals Inc (PMVP) , Passage Bio Inc (PASG) , Alector Inc (ALEC) , Turnstone Biologics Corp (TSBX) , Disc Medicine Inc (IRON) , Adaptimmune Therapeutics PLC (ADAP) , Decibel Therapeutics Inc (DBTX) , NextCure Inc (NXTC) , Arcutis Biotherapeutics Inc (ARQT) , Xtant Medical Holdings Inc (XTNT) , Cartesian Therapeutics Inc (RNAC) , Spyre Therapeutics Inc (SYRE) , resTORbio Inc (TORC) , Kinnate Biopharma Inc (KNTE) , Galecto Inc (GLTO) , Aerpio Pharmaceuticals Inc (ARPO) , LogicBio Therapeutics Inc (LOGC) , Kala Bio Inc (KALA) , Acutus Medical Inc (AFIB) , Repare Therapeutics Inc (RPTX) , Inspire Medical Systems Inc (INSP) , Ikena Oncology Inc (IKNA) , Otonomy Inc (OTIC) , Pieris Pharmaceuticals Inc (PIRS) , Sientra Inc (SIENQ) , ViewRay Inc (VRAYQ) , Logic Devices Inc (LOGC) , Athersys Inc (ATHXQ) , Sorrento Tech Inc (ROKA) , SteadyMed Ltd (STDY) , Glaukos Corp (GKOS) , Tricida Inc (TCDAQ) . Details can be seen in Orbimed Advisors Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Orbimed Advisors Llc has not made any transactions after 2024-05-16 and currently still holds the listed stock(s).
Transaction Summary of Orbimed Advisors Llc
Orbimed Advisors Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Orbimed Advisors Llc owns 92 companies in total, including Arcutis Biotherapeutics Inc (ARQT) , Xtant Medical Holdings Inc (XTNT) , and LogicBio Therapeutics Inc (LOGC) among others .
Click here to see the complete history of Orbimed Advisors Llc’s form 4 insider trades.
Insider Ownership Summary of Orbimed Advisors Llc
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
ARQT | Arcutis Biotherapeutics Inc | 2022-06-24 | director & 10 percent owner |
XTNT | Xtant Medical Holdings Inc | 2018-02-14 | 10 percent owner |
LOGC | LogicBio Therapeutics Inc | 2020-10-01 | director & 10 percent owner |
2020-09-25 | director & 10 percent owner | ||
2023-05-22 | director & 10 percent owner | ||
2023-11-22 | 10 percent owner | ||
2022-01-26 | director & 10 percent owner | ||
2020-08-18 | director | ||
2021-07-19 | director & 10 percent owner | ||
2020-07-16 | 10 percent owner | ||
2020-06-30 | director | ||
2021-09-07 | director | ||
2022-11-25 | 10 percent owner | ||
2021-03-30 | director | ||
2020-04-16 | 10 percent owner | ||
2020-04-13 | director | ||
2021-07-16 | director & 10 percent owner | ||
2021-01-07 | 10 percent owner | ||
2023-06-28 | 10 percent owner | ||
2019-11-22 | director & 10 percent owner | ||
2022-11-25 | director & 10 percent owner | ||
2023-04-21 | 10 percent owner | ||
2022-09-12 | 10 percent owner | ||
2021-09-20 | director | ||
2019-06-24 | director & 10 percent owner | ||
2019-05-21 | 10 percent owner | ||
2019-05-13 | director & 10 percent owner | ||
2019-04-22 | director | ||
2019-02-19 | 10 percent owner | ||
2023-12-28 | director | ||
2018-12-11 | director & 10 percent owner | ||
2018-10-19 | director | ||
2018-10-03 | 10 percent owner | ||
2018-09-26 | 10 percent owner | ||
2018-08-30 | 10 percent owner | ||
2018-08-20 | director & 10 percent owner | ||
2018-07-23 | 10 percent owner | ||
2018-07-17 | 10 percent owner | ||
2020-12-08 | director & 10 percent owner | ||
2018-06-22 | director & 10 percent owner | ||
2018-06-06 | director | ||
2018-05-22 | 10 percent owner | ||
2018-04-30 | director & 10 percent owner | ||
2018-03-12 | 10 percent owner | ||
2018-03-06 | director | ||
2018-02-08 | 10 percent owner & other: See Remarks | ||
2017-08-28 | director | ||
2017-12-08 | director | ||
2017-11-15 | 10 percent owner | ||
2017-10-03 | 10 percent owner | ||
2017-02-21 | 10 percent owner | ||
2016-12-30 | director & 10 percent owner | ||
2016-11-29 | director & 10 percent owner | ||
2016-07-25 | 10 percent owner | ||
2016-06-27 | director & 10 percent owner | ||
2016-05-11 | 10 percent owner | ||
2015-11-30 | director | ||
2015-10-27 | director & 10 percent owner | ||
2015-10-12 | 10 percent owner | ||
2015-03-26 | director & 10 percent owner | ||
2014-07-01 | 10 percent owner | ||
2013-09-24 | other: Former 10% Owner | ||
2013-02-13 | 10 percent owner | ||
2013-01-30 | director | ||
2011-01-01 | director & 10 percent owner | ||
2012-03-12 | 10 percent owner | ||
2012-02-08 | 10 percent owner | ||
2011-04-26 | director & other: (1) | ||
2010-12-09 | director | ||
2010-04-30 | 10 percent owner | ||
2007-05-10 | 10 percent owner | ||
2009-05-22 | 10 percent owner | ||
2007-05-14 | director | ||
2017-03-15 | director & 10 percent owner | ||
2024-05-03 | 10 percent owner | ||
2021-02-17 | 10 percent owner | ||
2023-05-15 | director & 10 percent owner | ||
2020-12-08 | director & 10 percent owner | ||
2024-01-23 | director & 10 percent owner | ||
2024-01-25 | director & 10 percent owner | ||
2022-11-08 | director & 10 percent owner | ||
2023-07-17 | director & 10 percent owner | ||
2023-05-05 | director | ||
2023-08-15 | director & 10 percent owner | ||
2023-12-18 | director & 10 percent owner | ||
2021-12-29 | director | ||
2022-12-23 | director & 10 percent owner | ||
2021-03-30 | director | ||
2022-09-19 | director & 10 percent owner | ||
2023-08-29 | director | ||
2024-05-16 | director & 10 percent owner | ||
2023-07-20 | director & 10 percent owner |
Orbimed Advisors Llc Latest Holdings Summary
Orbimed Advisors Llc currently owns a total of 75 stocks. Among these stocks, Orbimed Advisors Llc owns 5,316,355 shares of Synthorx Inc (THOR) as of December 11, 2018, with a value of $361 Million and a weighting of 9.87%. Orbimed Advisors Llc owns 13,822,463 shares of Prevail Therapeutics Inc (PRVL) as of June 24, 2019, with a value of $318 Million and a weighting of 8.68%. Orbimed Advisors Llc also owns 14,756,096 shares of Edgewise Therapeutics Inc (EWTX) as of January 23, 2024, with a value of $257 Million and a weighting of 7.03%. The other 72 stocks Loxo Oncology Inc (LOXO) , SpringWorks Therapeutics Inc (SWTX) , Audentes Therapeutics Inc (BOLD) , Principia Biopharma Inc (PRNB) , Enliven Therapeutics Inc (ELVN) , Turning Point Therapeutics Inc (TPTX) , Relypsa Inc (RLYP) , Rhythm Pharmaceuticals Inc (RYTM) , Supernus Pharmaceuticals Inc (SUPN) , ARS Pharmaceuticals Inc (SPRY) , NxStage Medical Inc (NXTM) , Third Harmonic Bio Inc (THRD) , Pacira BioSciences Inc (PCRX) , Theseus Pharmaceuticals Inc (THRX) , Mirati Therapeutics Inc (MRTX) , CTI BioPharma Corp (CTIC) , Fusion Pharmaceuticals Inc (FUSN) , Intellia Therapeutics Inc (NTLA) , Keros Therapeutics Inc (KROS) , Silverback Therapeutics Inc (SBTX) , Verona Pharma PLC (VRNA) , Terns Pharmaceuticals Inc (TERN) , Prelude Therapeutics Inc (PRLD) , Dimension Therapeutics Inc (DMTX) , ArriVent BioPharma Inc (AVBP) , Imara Inc (IMRA) , Compass Therapeutics Inc (CMPX) , CalciMedica Inc (CALC) , scPharmaceuticals Inc (SCPH) , NeuroPace Inc (NPCE) , Intercept Pharmaceuticals Inc (ICPT) , ORIC Pharmaceuticals Inc (ORIC) , Alpine Immune Sciences Inc (ALPN) , TELA Bio Inc (TELA) , Adicet Bio Inc (ACET) , 89bio Inc (ETNB) , Corvus Pharmaceuticals Inc (CRVS) , Constellation Pharmaceuticals Inc (CNST) , SI-BONE Inc (SIBN) , Janux Therapeutics Inc (JANX) , PMV Pharmaceuticals Inc (PMVP) , Passage Bio Inc (PASG) , Alector Inc (ALEC) , Turnstone Biologics Corp (TSBX) , Disc Medicine Inc (IRON) , Adaptimmune Therapeutics PLC (ADAP) , Decibel Therapeutics Inc (DBTX) , NextCure Inc (NXTC) , Arcutis Biotherapeutics Inc (ARQT) , Xtant Medical Holdings Inc (XTNT) , Cartesian Therapeutics Inc (RNAC) , Spyre Therapeutics Inc (SYRE) , resTORbio Inc (TORC) , Kinnate Biopharma Inc (KNTE) , Galecto Inc (GLTO) , Aerpio Pharmaceuticals Inc (ARPO) , LogicBio Therapeutics Inc (LOGC) , Kala Bio Inc (KALA) , Acutus Medical Inc (AFIB) , Repare Therapeutics Inc (RPTX) , Inspire Medical Systems Inc (INSP) , Ikena Oncology Inc (IKNA) , Otonomy Inc (OTIC) , Pieris Pharmaceuticals Inc (PIRS) , Sientra Inc (SIENQ) , ViewRay Inc (VRAYQ) , Logic Devices Inc (LOGC) , Athersys Inc (ATHXQ) , Sorrento Tech Inc (ROKA) , SteadyMed Ltd (STDY) , Glaukos Corp (GKOS) , Tricida Inc (TCDAQ) have a combined weighting of 74.42% among all his current holdings.
Latest Holdings of Orbimed Advisors Llc
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
THOR | Synthorx Inc | 2018-12-11 | 5,316,355 | 67.99 | 361,458,976 |
PRVL | Prevail Therapeutics Inc | 2019-06-24 | 13,822,463 | 23.00 | 317,916,649 |
EWTX | Edgewise Therapeutics Inc | 2024-01-23 | 14,756,096 | 17.44 | 257,346,314 |
LOXO | Loxo Oncology Inc | 2017-12-08 | 941,000 | 234.66 | 220,815,060 |
SWTX | SpringWorks Therapeutics Inc | 2022-09-12 | 5,599,842 | 38.91 | 217,889,852 |
BOLD | Audentes Therapeutics Inc | 2018-03-12 | 3,539,997 | 59.97 | 212,293,620 |
PRNB | Principia Biopharma Inc | 2019-05-21 | 1,605,713 | 100.05 | 160,651,586 |
ELVN | Enliven Therapeutics Inc | 2024-05-16 | 7,663,349 | 20.93 | 160,393,895 |
TPTX | Turning Point Therapeutics Inc | 2019-04-22 | 2,027,550 | 76.01 | 154,114,076 |
RLYP | Relypsa Inc | 2016-07-25 | 3,356,400 | 31.99 | 107,371,236 |
RYTM | Rhythm Pharmaceuticals Inc | 2018-05-22 | 2,750,079 | 38.58 | 106,098,048 |
SUPN | Supernus Pharmaceuticals Inc | 2013-02-13 | 3,000,000 | 27.92 | 83,760,000 |
SPRY | ARS Pharmaceuticals Inc | 2023-08-29 | 9,240,887 | 8.94 | 82,613,530 |
NXTM | NxStage Medical Inc | 2010-12-09 | 2,690,476 | 30.00 | 80,714,280 |
THRD | Third Harmonic Bio Inc | 2022-09-19 | 5,779,071 | 13.26 | 76,630,481 |
PCRX | Pacira BioSciences Inc | 2012-03-12 | 2,446,000 | 30.52 | 74,651,920 |
THRX | Theseus Pharmaceuticals Inc | 2023-07-17 | 17,713,600 | 4.06 | 71,917,216 |
MRTX | Mirati Therapeutics Inc | 2014-07-01 | 1,167,000 | 58.70 | 68,502,900 |
CTIC | CTI BioPharma Corp | 2021-01-07 | 7,520,600 | 9.09 | 68,362,254 |
FUSN | Fusion Pharmaceuticals Inc | 2020-06-30 | 3,122,770 | 21.55 | 67,295,694 |
NTLA | Intellia Therapeutics Inc | 2016-05-11 | 2,662,180 | 23.25 | 61,895,685 |
KROS | Keros Therapeutics Inc | 2020-04-13 | 1,119,812 | 49.53 | 55,464,288 |
SBTX | Silverback Therapeutics Inc | 2020-12-08 | 8,740,888 | 5.87 | 51,309,013 |
VRNA | Verona Pharma PLC | 2023-05-15 | 3,777,778 | 12.10 | 45,711,114 |
TERN | Terns Pharmaceuticals Inc | 2022-12-23 | 7,619,135 | 5.88 | 44,800,514 |
PRLD | Prelude Therapeutics Inc | 2023-05-22 | 10,646,056 | 3.56 | 37,899,959 |
DMTX | Dimension Therapeutics Inc | 2015-10-27 | 5,397,698 | 5.95 | 32,116,303 |
AVBP | ArriVent BioPharma Inc | 2024-01-30 | 1,513,664 | 18.33 | 27,745,461 |
IMRA | Imara Inc | 2021-07-16 | 4,199,068 | 6.32 | 26,538,110 |
CMPX | Compass Therapeutics Inc | 2022-11-08 | 18,791,422 | 1.34 | 25,180,505 |
CALC | CalciMedica Inc | 2020-09-25 | 4,163,347 | 5.63 | 23,418,827 |
SCPH | scPharmaceuticals Inc | 2022-11-25 | 5,559,528 | 4.02 | 22,349,303 |
NPCE | NeuroPace Inc | 2024-05-03 | 3,406,335 | 6.47 | 22,038,987 |
ICPT | Intercept Pharmaceuticals Inc | 2015-03-26 | 1,120,324 | 19.00 | 21,286,156 |
ORIC | ORIC Pharmaceuticals Inc | 2021-03-30 | 2,212,571 | 8.66 | 19,160,865 |
ALPN | Alpine Immune Sciences Inc | 2023-12-28 | 264,315 | 64.97 | 17,172,546 |
TELA | TELA Bio Inc | 2023-04-21 | 2,835,542 | 5.71 | 16,190,945 |
ACET | Adicet Bio Inc | 2024-01-25 | 11,447,140 | 1.36 | 15,568,110 |
ETNB | 89bio Inc | 2022-01-26 | 1,829,436 | 8.30 | 15,184,319 |
CRVS | Corvus Pharmaceuticals Inc | 2021-09-20 | 6,943,654 | 2.16 | 14,998,293 |
CNST | Constellation Pharmaceuticals Inc | 2018-07-23 | 417,921 | 33.99 | 14,205,135 |
SIBN | SI-BONE Inc | 2018-10-19 | 985,368 | 13.75 | 13,548,810 |
JANX | Janux Therapeutics Inc | 2021-12-29 | 231,098 | 48.52 | 11,212,875 |
PMVP | PMV Pharmaceuticals Inc | 2023-11-22 | 6,475,291 | 1.71 | 11,072,748 |
PASG | Passage Bio Inc | 2023-06-28 | 8,034,000 | 1.24 | 9,962,160 |
ALEC | Alector Inc | 2020-04-16 | 1,906,718 | 4.77 | 9,095,045 |
TSBX | Turnstone Biologics Corp | 2023-07-20 | 3,099,265 | 2.81 | 8,708,935 |
IRON | Disc Medicine Inc | 2023-12-18 | 224,405 | 36.57 | 8,206,491 |
ADAP | Adaptimmune Therapeutics PLC | 2018-06-06 | 4,901,310 | 1.01 | 4,950,323 |
DBTX | Decibel Therapeutics Inc | 2021-02-17 | 883,418 | 4.91 | 4,337,582 |
NXTC | NextCure Inc | 2019-05-13 | 2,711,013 | 1.35 | 3,659,868 |
ARQT | Arcutis Biotherapeutics Inc | 2022-06-24 | 415,142 | 7.88 | 3,271,319 |
XTNT | Xtant Medical Holdings Inc | 2018-02-14 | 3,316,128 | 0.72 | 2,371,032 |
RNAC | Cartesian Therapeutics Inc | 2016-06-27 | 60,847 | 35.77 | 2,176,497 |
SYRE | Spyre Therapeutics Inc | 2017-02-21 | 58,781 | 34.10 | 2,004,432 |
TORC | resTORbio Inc | 2018-01-30 | 690,055 | 2.28 | 1,573,325 |
KNTE | Kinnate Biopharma Inc | 2023-05-05 | 450,000 | 2.65 | 1,192,500 |
GLTO | Galecto Inc | 2023-08-15 | 1,510,375 | 0.54 | 808,051 |
ARPO | Aerpio Pharmaceuticals Inc | 2020-12-08 | 346,265 | 2.20 | 761,783 |
LOGC | LogicBio Therapeutics Inc | 2020-10-01 | 296,296 | 2.07 | 613,333 |
KALA | Kala Bio Inc | 2018-02-08 | 68,957 | 6.74 | 464,501 |
AFIB | Acutus Medical Inc | 2021-07-19 | 6,553,408 | 0.05 | 349,297 |
RPTX | Repare Therapeutics Inc | 2021-09-07 | 96,190 | 3.53 | 339,551 |
INSP | Inspire Medical Systems Inc | 2020-08-18 | 1,784 | 148.42 | 264,781 |
IKNA | Ikena Oncology Inc | 2021-03-30 | 130,924 | 1.74 | 227,808 |
OTIC | Otonomy Inc | 2015-11-30 | 1,850,094 | 0.01 | 15,726 |
PIRS | Pieris Pharmaceuticals Inc | 2018-04-30 | 486 | 10.30 | 5,005 |
SIENQ | Sientra Inc | 2015-10-12 | 178,500 | 0.03 | 4,820 |
VRAYQ | ViewRay Inc | 2018-08-20 | 69,617 | 0.00 | 1 |
LOGC | Logic Devices Inc | 2018-10-23 | 6,466,783 | 0.00 | 0 |
ATHXQ | Athersys Inc | 2011-04-26 | 0 | 0.00 | 0 |
ROKA | Sorrento Tech Inc | 2017-10-03 | 0 | 0.65 | 0 |
STDY | SteadyMed Ltd | 2018-08-30 | 0 | 4.73 | 0 |
GKOS | Glaukos Corp | 2018-03-06 | 0 | 111.63 | 0 |
TCDAQ | Tricida Inc | 2022-11-25 | 0 | 0.00 | 0 |
Holding Weightings of Orbimed Advisors Llc
Orbimed Advisors Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Orbimed Advisors Llc has made a total of 0 transactions in Synthorx Inc (THOR) over the past 5 years. The most-recent trade in Synthorx Inc is the acquisition of 1,363,636 shares on December 11, 2018, which cost Orbimed Advisors Llc around $15 Million.
According to the SEC Form 4 filings, Orbimed Advisors Llc has made a total of 1 transactions in Prevail Therapeutics Inc (PRVL) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prevail Therapeutics Inc is the acquisition of 882,352 shares on June 24, 2019, which cost Orbimed Advisors Llc around $15 Million.
According to the SEC Form 4 filings, Orbimed Advisors Llc has made a total of 4 transactions in Edgewise Therapeutics Inc (EWTX) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Edgewise Therapeutics Inc is the acquisition of 454,545 shares on January 23, 2024, which cost Orbimed Advisors Llc around $5 Million.
More details on Orbimed Advisors Llc's insider transactions can be found in the Insider Trading History of Orbimed Advisors Llc table.Insider Trading History of Orbimed Advisors Llc
- 1
Orbimed Advisors Llc Trading Performance
GuruFocus tracks the stock performance after each of Orbimed Advisors Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Orbimed Advisors Llc is 9.2%. GuruFocus also compares Orbimed Advisors Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Orbimed Advisors Llc within 3 months outperforms 64 times out of 117 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Orbimed Advisors Llc's insider trading performs compared to the benchmark.
Performance of Orbimed Advisors Llc
Orbimed Advisors Llc Ownership Network
Ownership Network List of Orbimed Advisors Llc
Ownership Network Relation of Orbimed Advisors Llc
Orbimed Advisors Llc Owned Company Details
What does Arcutis Biotherapeutics Inc do?
Who are the key executives at Arcutis Biotherapeutics Inc?
Orbimed Advisors Llc is the director & 10 percent owner of Arcutis Biotherapeutics Inc. Other key executives at Arcutis Biotherapeutics Inc include See Remarks Patrick Burnett , SVP and General Counsel Masaru Matsuda , and Chief Commercial Officer Larry Todd Edwards .
Arcutis Biotherapeutics Inc (ARQT) Insider Trades Summary
Over the past 18 months, Orbimed Advisors Llc made no insider transaction in Arcutis Biotherapeutics Inc (ARQT). Other recent insider transactions involving Arcutis Biotherapeutics Inc (ARQT) include a net sale of 42,938 shares made by Todd Franklin Watanabe , a net sale of 91,496 shares made by Patrick Burnett , and a net sale of 15,665 shares made by Masaru Matsuda .
In summary, during the past 3 months, insiders sold 115,402 shares of Arcutis Biotherapeutics Inc (ARQT) in total and bought 0 shares, with a net sale of 115,402 shares. During the past 18 months, 214,195 shares of Arcutis Biotherapeutics Inc (ARQT) were sold and 102,515 shares were bought by its insiders, resulting in a net sale of 111,680 shares.
Arcutis Biotherapeutics Inc (ARQT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arcutis Biotherapeutics Inc Insider Transactions
Orbimed Advisors Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Orbimed Advisors Llc. You might contact Orbimed Advisors Llc via mailing address: 601 Lexington Avenue, 54th Floor, New York Ny 10022.